Ketamine, a wellâ€established dissociative anesthetic, has recently gained significant attention for its rapidâ€acting antidepressant effects, particularly in treatmentâ€resistant depression.
In this study, we developed and validated a stateâ€ofâ€theâ€art liquid chromatographyâ€“tandem mass spectrometry (LCâ€“MS/MS) method for the bioanalysis of ketamine and its metabolites, norketamine, dehydronorketamine (DHNK), and (2R,6R)â€hydroxynorketamine (HNK), in human plasma.
The method features a small sample volume, a streamlined protein precipitation protocol, and a rapid sample runtime.
The mobile phase gradient is composed of an aqueous ammonium hydrogen carbonate solution and pure acetonitrile.
Using positive electrospray ionization, linear quantification ranges of 1â€“1,000 ng/mL were established for ketamine and norketamine, while ranges of 0.25â€“100 ng/mL for DHNK and 2.5â€“1,000 ng/mL for (2R,6R)â€HNK were achieved.
The method demonstrated high accuracy, precision, selectivity, and sensitivity, along with consistent matrix effects, efficient extraction recovery, and analyte stability.
Finally, the method was successfully applied to assess the pharmacokinetics of six clinical trial participants.
Overall, this LCâ€“MS/MS method offers a robust and efficient approach for the achiral quantification of ketamine and its metabolites in human plasma.
Its minimal sample preparation and reduced analytical runtime make it particularly wellâ€suited for clinical studies, drug monitoring, and forensic investigations.
The arylcyclohexylamine ketamine is a dissociative anesthetic that has gained increasing interest in both clinical and research contexts.
Originally developed as a safer alternative to phencyclidine (PCP), ketamine was approved for human use by the US Food and Drug Administration (FDA) in 1970 and has since been widely utilized in both human and veterinary medicine, primarily for induction and maintenance of anesthesia (Dinisâ€Oliveira2017; Hirota and Lambert2022).
Ketamine contains a chiral center and is typically found as a racemic mixture.
However, the isomer S(+)â€ketamine is often used as an anesthetic due to its greater analgesic potency and less drowsiness, lethargy, and cognitive impairment (Dinisâ€Oliveira2017; Hirota and Lambert2022; Passie et al.2021).
Pharmacologically, ketamine acts primarily as a noncompetitiveNâ€methylâ€Dâ€aspartate (NMDA) receptor antagonist.
It has been demonstrated to bind to the allosteric PCP binding site within the channel pore.
The mechanism of action of ketamine involves the inhibition of NMDA receptor activity by reducing calcium ion influx.
This results in the disruption of the transmission of pain signals and the exertion of dissociative, anesthetic, amnesic, analgesic, and antidepressant effects (Dinisâ€Oliveira2017; Schep et al.2023; Zanos and Gould2018; Zanos et al.2018).
S(+)â€ketamine has been shown to exhibit approximately fourfold higher affinity for the PCP binding site than R(âˆ’)â€ketamine, thereby explaining its greater potency in producing these effects (Zanos et al.2018).
In addition to its NMDA antagonism, ketamine has been shown to interact with opioid receptors, monoaminergic pathways, cholinergic receptors (both muscarinic and nicotinic acetylcholine receptors), and other targets, which contribute to its complex pharmacodynamic profile.
In contrast to other anesthetics, ketamine does not relevantly interfere with ğ›¾â€aminobutyric acid (GABA) receptors (Dinisâ€Oliveira2017; Hirota and Lambert2022; Zanos and Gould2018; Zanos et al.2018).
Ketamine is stereoselectively metabolized primarily in the liver by cytochrome P450 (CYP) enzymes.
The initial metabolic step is Nâ€demethylation to norketamine, primarily via CYP3A4 and CYP2B6, with contributions from CYP2C9, CYP2C19, CYP2A6, and CYP2D6 (Dinisâ€Oliveira2017; Kamp, Jonkman, et al.2020; Zanos et al.2018).
Norketamine, an active metabolite that also inhibits NMDA receptors, exhibits psychoactive and anesthetic properties.
Norketamine is further metabolized by hydroxylation, mainly via CYP2B6 and CYP2A6, to form hydroxynorketamine (HNK), including isomers with antidepressant and analgesic effects such as (2R,6R)â€HNK and (2S,6S)â€HNK (Dinisâ€Oliveira2017; Kamp, Jonkman, et al.2020; Zanos et al.2018).
Furthermore, the formation of dehydronorketamine (DHNK) can be observed either by nonenzymatic dehydration of the 5â€HNK isoform or directly via CYP2B6 from norketamine.
HNK can also be Oâ€glucuronidated by uridineâ€5â€²â€diphosphoâ€glucuronosyltransferases (UGTs) to form HNKâ€glucuronides (Dinisâ€Oliveira2017; Kamp, Jonkman, et al.2020; SandbaumhÃ¼ter and Thormann2018; Zanos et al.2018).
Other minor metabolic pathways that have been reported include the hydroxylation of ketamine to hydroxyketamine and the formation of urinary phenolic metabolites of ketamine and norketamine (Dinisâ€Oliveira2017; Zanos et al.2018).
Lately, ketamine has received renewed attention for its rapidâ€acting antidepressant properties, particularly in treatmentâ€resistant major depressive disorder (MDD) and suicidal ideation (Glue et al.2024; Hirota and Lambert2022; Williams et al.2019; Zolghadriha et al.2024).
At subanesthetic doses, typically administered intravenously or intranasally, ketamine has demonstrated significant and rapid mood improvement in clinical trials, often within hours of administration.
This is in clear contrast to conventional antidepressants, which usually take weeks to achieve efficacy (Rosenblat et al.2023; Williams et al.2019; Zolghadriha et al.2024).
Furthermore, it has been suggested that the metabolites (2S,6S)â€HNK and (2R,6R)â€HNK exert an antidepressant effect but lack the typical side effects associated with ketamine (Loan Nguyen et al.2024; Zanos et al.2016; Zanos et al.2018).
These findings have sparked interest in the development of ketamine analogs and derivatives, including esketamine, which was FDAâ€approved in 2019 as a nasal spray for depression in combination therapy and as a standâ€alone therapy in 2025 (Reuters2025).
In recent years, a considerable number of LCâ€“MS methods have been developed for the detection and quantification of ketamine and metabolites in various biological matrices, including plasma, serum, urine, feces, milk, cerebrospinal fluid, and brain tissue.
Advanced methods also include enantiomeric separation using column switching and chiral columns (Harun et al.2010; Hasan et al.2017; Kurzweil et al.2020; Moaddel et al.2010; Rhee et al.2021; Rochani et al.2020; Rodriguez Rosas et al.2003; Shahane et al.2023; Toki et al.2023).
Sample preparation often involves laborious liquidâ€“liquid or solidâ€phase extraction.
Moreover, the methods entail extensive sample runtimes, which are impractical for the analysis of a large number of study samples (Harun et al.2010; Hasan et al.2017; Kurzweil et al.2020; Moaddel et al.2010; Rhee et al.2021; Rochani et al.2020; Rodriguez Rosas et al.2003; Shahane et al.2023; Toki et al.2023).
Consequently, the method developed and validated in this study was designed to optimize sample preparation by reducing laborâ€intensive steps and decreasing the runtime of a single sample.
This enhances its suitability for analyzing large numbers of clinical study samples.
Furthermore, the incorporation of metabolites norketamine, DHNK, and (2R,6R)â€HNK provides comprehensive insights into ketamine's in vivo metabolism and pharmacokinetics.
Finally, a subset of clinical study samples was analyzed to demonstrate method functionality.
Ketamine hydrochloride (99.9% purity, 1 mg/mL free base in methanol), norketamine hydrochloride (99.5% purity, 1 mg/mL free base in methanol), DHNK hydrochloride (99.6% purity, 0.1 mg/mL free base in acetonitrile), and the deuteriated internal standards ketamineâ€d4hydrochloride (99.7% purity, 1 mg/mL free base in methanol) and norketamineâ€d4hydrochloride (99.8% purity, 0.1 mg/mL free base in methanol) were acquired from Cerilliant (Round Rock, TX, USA).
(2R,6R)â€HNK (99.2% purity) and (2S,6S)â€HNK (99.1% purity) were obtained from Sigmaâ€Aldrich (St.
Louis, MO, USA).
LCâ€“MS grade water, methanol, isopropanol, ammonium hydrogen carbonate, and ammonia solution 25% were provided by Merck (Darmstadt, Germany).
Dimethyl sulfoxide (DMSO) and acetonitrile were obtained from Sigmaâ€Aldrich and Thermo Fisher Scientific (Waltham, MA, USA), respectively.
Blank human plasma was drawn from voluntary donors at the University Hospital Basel and collected into lithium heparinâ€coated Sâ€Monovette tubes (Sarstedt, NÃ¼mbrecht, Germany) to prevent blood clotting.
To yield the plasma from whole blood, the tubes were centrifuged at 1811 Ã—gfor 10 min (5810 R centrifuge, Eppendorf, Hamburg, Germany).
For each analyte, two separate stock solutions were prepared: one for calibrators (CAL) and one for quality control (QC) samples.
These samples were either directly obtained or prepared.
Using the CAL or QC stock solutions, each containing 1 mg/mL ketamine, 1 mg/mL norketamine, 1 mg/mL (2R,6R)â€HNK, or 0.1 mg/mL DHNK, two stock mixtures were prepared in DMSO.
These stock mixtures contained 200 Î¼g/mL of ketamine, norketamine, and (2R,6R)â€HNK, and 20 Î¼g/mL of DHNK.
All stock solutions were stored at âˆ’20 Â°C.
The 200â€Î¼g/mL stock mixtures were serially diluted in DMSO.
The dilution steps were performed to obtain samples with final concentrations ranging from 0.1 to 100 Î¼g/mL for ketamine and norketamine, from 0.025 to 10 Î¼g/mL for DHNK, and from 0.25 to 100 Î¼g/mL for (2R,6R)â€HNK.
Subsequently, the CAL and QC dilutions were used to spike pooled plasma from seven donors at a 1:100 (v/v) ratio.
This resulted in CAL lines ranging from 1 to 1,000 ng/mL for ketamine and norketamine, from 0.25 to 100 ng/mL for DHNK, and from 2.5 to 1,000 ng/mL for (2R,6R)â€HNK.
QC samples were prepared analogously to CAL samples.
For each substance, four QC levels were included: the lower limit of quantification (LLOQ), low QC (LQC), mid QC (MQC), and high QC (HQC).
The QC levels for ketamine and norketamine were set at 1, 2.5, 50, and 500 ng/mL; for DHNK at 0.25, 0.5, 5, and 50 ng/mL; for (2R,6R)â€HNK at 2.5, 5, 50, and 500 ng/mL.
The analysis was performed using a highâ€performance liquid chromatograph (HPLC, Shimadzu, Kyoto, Japan) coupled to an API 5500 triple quadrupole tandem mass spectrometer (MS, AB Sciex, Ontario, Canada).
The HPLC system consisted of an autosampler (set to 10 Â°C), three pumps (A, B, and C), a system controller, two degassing units, and a column oven (set to 35 Â°C).
Best chromatographic results were achieved using a Symmetry C18 column (3.5 Î¼m, 100 Ã…, 75 Ã— 4.6 mm, Waters, Milford, USA).
Mobile phase A comprised a 20â€mM ammonium hydrogen carbonate solution in water, adjusted to pH 9 with 25% ammonia solution.
Mobile phase B consisted of pure acetonitrile.
Before and after each sample injection (10 Î¼L injection volume), the autosampler port was purged with 500 Î¼L washing solution (water, acetonitrile, methanol, and isopropanol 1:1:1:1, v/v).
The injected sample was first transported to a Tâ€union (located in front of the column) by pumps A and B, where it was diluted with mobile phase A by pump C (0.7 mL/min, 0â€“0.5 min).
The initial total flow of pump A (90%) and pump B (10%) was set to 0.7 mL/min and was increased to 1.4 mL/min after 0.5 min.
The concentration of mobile phase B was linearly raised from 10% at 0.5 min to 95% after 3.0 min.
Subsequently, mobile phase B concentration remained at 95% for 1.0 min to wash the column.
Next, the concentration of mobile phase B was returned to 10% until 4.5 min to recondition the column.
The eluent was directed into the mass spectrometer from 1.4 to 3.5 min and otherwise directed into the waste.
Using this method, ketamine had a retention time of 2.92 min, norketamine 2.61 min, DHNK 2.51 min, and (2R,6R)â€HNK 1.91 min.
The chromatographic separation of all substances is shown in Figure1.
Chromatographic separation of ketamine (100 ng/mL), norketamine (100 ng/mL), dehydronorketamine (DHNK; 10 ng/mL), (2R,6R)â€hydroxynorketamine (HNK; 100 ng/mL), ketamineâ€d4(10 ng/mL), and norketamineâ€d4(20 ng/mL) in pooled human plasma.
The analytes were ionized using positive electron spray ionization (ESI) and detected with multiple reaction monitoring (MRM) in positive ion mode (Table1).
The mass spectrometer parameters were set as follows: source temperature (TEM), 500 Â°C; ion spray voltage (IS), 5500 V; nebulizer gas (ion source gas 1, GS1), 30 psi; heater gas (ion source gas 2, GS2), 60 psi; curtain gas (CUR), 30 psi; and collision gas (CAD), 6 psi.
The LCâ€“MS/MS system was operated using Analyst Instrumental Control and Data Processing software (version 1.7.2, AB Sciex) and MultiQuant software (version 3.0.3, AB Sciex).
Mass spectrometry settings for the quantification of ketamine, norketamine, dehydronorketamine (DHNK), (2R,6R)â€hydroxynorketamine (HNK), and their deuterated internal standards.
Samples were extracted by simple protein precipitation.
A volume of 50 Î¼L plasma was aliquoted and extracted with 150 Î¼L internal standard solution (10 ng/mL ketamineâ€d4and 20 ng/mL norketamineâ€d4in acetonitrile) in Matrix tubes (0.7 mL, 96â€deepwell rack, Thermo Fisher Scientific).
Afterward, the samples were vortexed for 5 min on a multitube vortexer (VXâ€2500, VWR, Radnor, PA, USA).
To obtain a supernatant free of precipitated plasma proteins, the samples were centrifuged for 30 min at 3220 Ã—gand 10 Â°C.
The method was validated in accordance with the US Food and Drug Administration's (FDA) Bioanalytical Method Validation Guidance for Industry (United States Food and Drug Administration2018), following an approach used in earlier validations (Luethi et al.2022; Luethi et al.2024; Thomann et al.2022; Thomann et al.2025; Thomann et al.2024).
The validated parameters included linearity, carryover, accuracy, precision, selectivity, sensitivity, matrix effects, extraction recovery, and analyte stability.
At least two CAL lines were included in each analytical run to ensure linearity.
A CAL line consisted of 10 individual CAL samples ranging from 1 to 1,000 ng/mL for ketamine and norketamine, 9 CAL samples ranging from 0.25 to 100 ng/mL for DHNK, or 9 CAL samples ranging from 2.5 to 1,000 ng/mL for (2R,6R)â€HNK.
A blank sample (matrix extracted with internal standard) and a double blank sample (matrix extracted with pure acetonitrile) were included prior to each CAL line.
Using MultiQuant, a linear regression was generated by plotting the analyte peak area against the internal standard peak area with a weighting factor of 1/x2.
The measured CAL concentrations were compared with the nominal CAL values, and the difference between the two values could not exceed Â±15% (Â±20% for the LLOQ).
A valid CAL line required at least 75% of the CAL points to be included, along with one LLOQ and one upper limit of quantification (ULOQ) sample; the correlation coefficient (R) had to be â‰¥ 0.99.
To assess intraâ€ and interâ€assay accuracy and precision, seven replicates of LLOQ, LQC, MQC, and HQC samples were analyzed across three validation runs conducted on three separate days.
The accuracy was assessed by calculating the percentage deviation of QC sample concentrations from their nominal values.
Acceptable accuracy ranged from 85% to 115%, except for the LLOQ, where a range of 80%â€“120% was permitted.
Precision was evaluated by calculating the coefficient of variation (%CV = [standard deviation/mean] Ã— 100), which was required to be within Â±15% (Â±20% for the LLOQ).
Method selectivity and sensitivity were evaluated using blank, double blank, and LLOQ plasma samples obtained from seven individual donors.
Selectivity was considered adequate if the analyte signal at the LLOQ was at least fivefold higher than any detected noise signal in the blank and double blank samples.
Sensitivity was confirmed when the mean accuracy of the LLOQ samples fell within the range of 80%â€“120%.
The matrix effect was assessed by comparing the analyte peak area in plasma samples to the analyte peak area in matrixâ€free samples.
Plasma from seven different donors was spiked with the analytes at three QC levels (LQC, MQC, and HQC), while matrixâ€free samples were prepared by spiking water with the analytes.
Only a consistent matrix effect across all plasma batches and QC levels was deemed acceptable, as evidenced by a %CV of â‰¤ 15%.
Extraction recovery was evaluated by spiking blank plasma samples from seven different donors with the analyte both before and after the extraction process at the LLOQ, LQC, MQC, and HQC levels.
At each QC level, the analyte peak areas obtained before and after extraction were compared.
The peak area of postextraction spiked supernatants was considered to represent 100% recovery.
The method was considered valid when recovery was consistent, precise, and reproducible across all QC levels and plasma batches.
The stability of the analytes was evaluated by assessing seven replicates of LQC, MQC, and HQC samples under different storage and handling conditions.
Samples were kept at room temperature for 8 h (benchtop stability), underwent 3 freezeâ€“thaw cycles prior to analysis (freezeâ€“thaw stability), or were stored at âˆ’20 Â°C or âˆ’80 Â°C for 3 months (mediumâ€term stability I and II).
Two freshly prepared CAL lines and four freshly prepared sets of LQC, MQC, and HQC samples were used for the assessment.
Additionally, to assess the feasibility of reinjection following an instrument failure during an analytical run, samples were extracted, initially analyzed, and then reanalyzed after storage under one of the following conditions: in the autosampler for 24 h at 10 Â°C (autosampler stability), at âˆ’20 Â°C for 7 days (extract stability I), or at âˆ’80 Â°C for 7 days (extract stability II).
The same acceptance criteria applied to accuracy and precision assessments were used for stability evaluation.
A subset of clinical phase I study samples was analyzed to demonstrate the suitability of the validated method.
The study (NCT06180759) was performed at the University Hospital Basel; it received approval from the Ethics Committee of Northwest and Central Switzerland (BASEC 2023â€01813) and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.
Six participants received an intravenous infusion of ketamine at a concentration of 1.0 mg/min for 55 min.
A total of 17 blood samples were collected at predetermined time points: 0, 5, 10, 15, 20, 30, 40, 50, 55, 60, 65, 70, 75, 85, 95, 105, and 115 min.
All samples were collected into lithiumâ€heparinâ€coated Sâ€Monovette tubes (Sarstedt) and subsequently subjected to a centrifugal process at 1811 Ã—gfor a duration of 10 min to yield plasma.
Thereafter, the samples were stored at âˆ’80 Â°C until further analysis.
Pharmacokinetic parameters were calculated using Phoenix WinNonlin software (version 8.1.0, Certara, Princeton, USA).
Several LCâ€“MS methods have been developed for the analysis of ketamine and its metabolites across various biological matrices.
However, many of these approaches involve lengthy analysis times or laborâ€intensive extraction and sample preparation procedures (Harun et al.2010; Hasan et al.2017; Kurzweil et al.2020; Moaddel et al.2010; Rhee et al.2021; Rochani et al.2020; Rodriguez Rosas et al.2003).
Furthermore, not all methods include metabolites such as DHNK or (2R,6R)â€HNK, and in some cases, ketamine is analyzed as just one among dozens of compounds in broadâ€spectrum screening assays (Harun et al.2010; Kurzweil et al.2020; Rhee et al.2021; Rochani et al.2020; Rodriguez Rosas et al.2003).
In this study, we aimed to develop and optimize an LCâ€“MS/MS method for ketamine, specifically designed for the analysis of a large number of clinical study samples.
Our focus was on achieving a rapid and streamlined protocol while ensuring the inclusion of relevant ketamine metabolites.
Plasma samples were prepared and extracted using a simple protein precipitation method.
A sample volume of only 50 Î¼L was mixed with 150 Î¼L of an internal standard solution, followed by centrifugation to obtain the supernatant, which was then injected into the HPLC system.
All analytes were ionized using positive ESI mode.
To optimize ionization parameters, each compound was initially introduced directly into the mass spectrometer.
The two mass transitions with the highest signal intensities were selected for each analyte and designated as the quantifier and qualifier transitions.
The transitions chosen for this method were largely consistent with those reported in previous studies (Harun et al.2010; Hasan et al.2017; Kurzweil et al.2020; Moaddel et al.2010; Rhee et al.2021; Shahane et al.2023; Toki et al.2023).
Optimal chromatographic separation of the analytes was achieved using a Symmetry C18 column (3.5 Î¼m, 100 Ã…, 75 Ã— 4.6 mm; Waters).
Both (2R,6R)â€HNK and (2S,6S)â€HNK were initially tuned into the MS without significant differences in their MRM configurations.
However, since the analytes could not be separated using this achiral approach, the method validation was conducted for (2R,6R)â€HNK only.
A chromatogram of the separated analytes and their internal standards is shown in Figure1.
The method demonstrated linearity across a concentration range of 1â€“1,000 ng/mL for ketamine and its main metabolite norketamine.
For DHNK and (2R,6R)â€HNK, linear ranges of 0.25â€“100 and 2.5â€“1,000 ng/mL, respectively, were achieved.
In all cases, the correlation coefficient (R) exceeded 0.998, indicating excellent linearity.
All measured values for each analyte remained within the acceptable deviation limits from the nominal concentrations (Â±15% and Â±20% for the LLOQ) across three analytical runs (TableS1).
For ketamine and norketamine, a mean carryâ€over of 25.7% and 25.4%, respectively, of the LLOQ peak area was observed in double blank samples following the injection of a ULOQ sample.
However, in a subsequent second double blank sample, the carryâ€over was reduced to 8.5% and 8.0%, respectively.
For DHNK and (2R,6R)â€HNK, the carryâ€over in the first double blank sample was 9.5% and 8.9%, respectively, and decreased to 3.2% and 2.9%, respectively, in the next sample.
Therefore, to mitigate carryâ€over for ketamine and norketamine, at least two double blank or solvent samples should be included after analyzing highly concentrated samples.
In contrast, carryâ€over for DHNK and (2R,6R)â€HNK remained within acceptable limits and did not necessitate additional blanks.
Intraâ€ and interâ€assay accuracy and precision for ketamine, norketamine, DHNK, and (2R,6R)â€HNK are presented in TableS2.
For this assessment, seven replicates at each QC level (LLOQ, LQC, MQC, and HQC) were analyzed across three independent assay runs.
Ketamine demonstrated interâ€assay accuracy ranging from 101.0% to 108.7%, with precision (%CV) between 2.4% and 10.2%; for norketamine, accuracy ranged from 99.5% to 118.3%, with precision between 3.2% and 10.3%; DHNK showed an accuracy of 89.8% to 109.3% and precision of 3.1% to 15.8%; (2R,6R)â€HNK exhibited accuracy between 95.0% and 106.1% and precision between 2.9% and 16.5%.
Overall, interâ€assay accuracy across all analytes ranged from 93.2% to 111.9% and interâ€assay precision ranged from 3.8% to 12.6%.
To assess selectivity and sensitivity, seven blank and double blank samples from individual donors were compared to LLOQ samples.
No interference from endogenous plasma components was observed for any of the analytes, demonstrating excellent selectivity (Figure2and TableS3).
The signalâ€toâ€noise ratio, determined by comparing peak areas of double blank or blank samples to those of the LLOQ, consistently exceeded 5:1 (Figure2).
Mean accuracy at the LLOQ ranged from 80.4% to 116.0%, with precision (%CV) between 6.5% and 9.3%, confirming the method's sensitivity (TableS4).
Selectivity of ketamine (a), norketamine (b), dehydronorketamine (DHNK; c), and (2R,6R)â€hydroxynorketamine (HNK; d) in human plasma.
The chromatograms are displayed as an overlay of seven blank samples (left side, black lines), seven double blank samples (right side, black lines), and seven lower limit of quantification (LLOQ; colored lines) samples.
Matrix effect and extraction recovery results are presented in TableS5.
The matrix effect was consistent for all analytes across all QC levels and plasma batches.
However, a slight but consistent ion suppression was observed for DHNK and (2R,6R)â€HNK.
The mean matrix effect was 102.4% for ketamine, 103.8% for norketamine, 83.9% for DHNK, and 80.7% for (2R,6R)â€HNK.
Extraction recovery was nearly complete for ketamine, norketamine, and (2R,6R)â€HNK, with mean values of 97.7%, 97.2%, and 98.2%, respectively.
In contrast, DHNK showed a moderately lower recovery of 75.2%.
The stability of ketamine, norketamine, DHNK, and (2R,6R)â€HNK under various conditions is presented in TableS6.
The assessed conditions include autosampler stability, extract stability, benchâ€top stability, freezeâ€“thaw stability, and mediumâ€term storage stability.
Across all conditions, QC levels, and analytes, accuracy ranged from 88.7% to 113.0%.
The analytes were not affected by stress conditions such as 3 freezeâ€“thaw cycles (accuracy of 90.7%â€“105.7%) or 8â€h benchâ€top exposure (accuracy of 88.7%â€“104.6%), nor by storage for 3 months at either âˆ’20 Â°C or âˆ’80 Â°C (accuracy of 89.4%â€“113.0%).
Furthermore, reinjection of extracted samples, which may be needed after an instrument failure, was feasible both the next day (accuracy of 95.7%â€“112.4%) and even 1 week later (accuracy of 93.4%â€“110.7%).
The stability of ketamine, norketamine, DHNK, and (2R,6R)â€HNK has previously been assessed by others under various storage conditions and in different matrices.
In general, the stability of all compounds was maintained in biological matrices for periods ranging from several weeks to several months when stored at âˆ’20 Â°C or lower (Hijazi et al.2001; Raja et al.2024).
Ketamine, formulated as a medical product for anesthesia, is deemed to be stable for several weeks even when exposed to temperatures up to 40 Â°C (Tran et al.2018; Usman et al.2024).
Additionally, norketamine has demonstrated stability in whole blood at ambient temperature for a minimum of 2 h (Tran et al.2018).
To demonstrate the suitability of the developed and validated method, plasma samples of six study participants were analyzed, and the pharmacokinetic parameters were assessed.
These samples were obtained from a phase I clinical trial investigating acute analgesic effects on experimentally induced nociceptive pain, hyperalgesia, and allodynia, using ketamine as a positive control.
The resulting pharmacokinetic profiles of ketamine, norketamine, DHNK, and (2R,6R)â€HNK are illustrated in Figure3and shown in TableS7.
Pharmacokinetic profiles of ketamine (a), norketamine (b), dehydronorketamine (DHNK; c), and hydroxynorketamine (HNK; d) in plasma of clinical study participants (n= 6, mean Â± SEM) receiving an intravenous infusion of 1.0 mg/min ketamine for 55 min.
The maximum plasma concentration (Cmax) of ketamine was 273.8 ng/mL, reached after 53.3 min (tmax), which coincided approximately with the end of the infusion.
The complexity of the disease reflects the convergence of diverse immunological and neurodegenerative processes that collectively intensify CNS damage.
One major immune-related feature of MS is the clonal expansion of B cells, a key population of leukocytes.
B cells play central roles in immunity by producing antibodies and presenting antigens to other immune components.
In MS, these cells become dysregulated, increasing immune activation within the CNS.
This heightened activity contributes to antibody production, antigen presentation, and the formation of ectopic follicle-like structures in the brain and spinal cord.
Such FLS create localized inflammatory niches that amplify immune-mediated injury and accelerate disease progression.
The emergence of these ectopic lymphoid structures is itself another immunological mechanism involved in MS pathology.
The MS-STAT Phase II study, though centered on SPMS, provides insights relevant to PPMS.
This study included 140 participants who received either 80 mg of simvastatin daily or placebo over two years.
The trial reported a 43% reduction in brain atrophy compared with placebo.
Improvements were also observed in EDSS disability levels and quality-of-life measures, though no major cognitive differences emerged between groups.